Head & Neck Cancer

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free survival versus standard care.

Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck.

GLP-1 drugs lowered rates of obesity-related cancers and death versus DPP-4s, with no increased cancer risk, study finds.

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma.

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.

The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma.

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.

Dr. Lillian L. Siu discussed potential risk factors and treatment strategies associated for patients with head and neck cancer.

April is Head and Neck Cancer Awareness Month, and it is important to be aware of early signs and symptoms of the disease, as well as when to seek care.

A patient with HPV-positive head and neck squamous cell carcinoma was dosed in a phase 1 clinical trial evaluating APR-1051.

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach this stage.

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally advanced head and neck cancer.

Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.

From the death of a Netflix actress due to stomach cancer complications to an NFL star sharing his chemo experience, here is this week’s cancer news.

A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck squamous cell carcinoma.

Missing weekly cisplatin cycles was associated with worse OS in patients with head and neck cancers, particularly for those with p16-negative tumors.

Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means for those with solid tumors.

From the death of folk music star Peter Yarrow of Peter, Paul and Mary to good news from broadcasting legend Dick Vitale, here is this week’s news.

Opdivo Qvantig received FDA approval for all previously approved indications in solid tumors.

Patients with a head and neck cancer subtype did not show differences in survival outcomes when treated with radiation versus transoral robotic surgery.

An oral gel to manage oral mucositis — or chemo mouth — may help alleviate the effects of the side effect related to chemotherapy and radiotherapy.

A Keytruda-based regimen given both before and after surgery for patients with head and neck squamous cell carcinoma may improve event-free survival.

In some patients with head and neck cancer, those who require dental care after cancer treatment may face financial burdens because of out-of-pocket costs.

In addition to increased treatment costs, patients with head and neck cancers also experienced therapy changes during the cisplatin shortage.